Sanofi 6-K includes Q3 press release: sales and earnings progress

Rhea-AI Filing Summary

Sanofi furnished a Form 6-K for October 2025, providing an update via an attached press release. Exhibit 99.1 is titled “Q3: continued sales and earnings progress” and is dated October 24, 2025. This filing shares the company’s quarterly narrative through that press release.

The report was signed on October 24, 2025 by Alexandra Roger, Head of Legal Corporate & Finance. Readers can reference Exhibit 99.1 for Sanofi’s Q3 themes around sales and earnings performance.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

46, avenue de la Grande Armée, 75017 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

In October 2025, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit Index

Exhibit No.			Description
Exhibit 99.1			Press release dated October 24, 2025: Q3: continued sales and earnings progress

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 24, 2025

SANOFI

By:

/s/ Alexandra Roger

Name:

Alexandra Roger

Title:

Head of Legal Corporate & Finance